Once For All to Acquire Nalanda Global
Once For All (the “Company”), a European leader in supply chain compliance and sustainable sourcing solutions for the built environment, is excited to announce the acquisition of Nalanda Global (“Nalanda”), a leading supply chain risk and compliance management software platform in Spain.
The transaction extends Once For All’s European footprint into Spain and enhances the differentiated offering of its technology platform, adding scale and the ability to aid in providing a broader product suite to its customer base. Similar to Once For All, Nalanda operates a SaaS-based network that helps enable contractors in multiple industries to manage the compliance of sub-contractors in their supply chain. Nalanda also brings additional worker-level compliance and health & safety solutions to Once For All’s product suite.
Founded in 2000 by a group of preeminent Spanish construction companies, Nalanda is based in Madrid, Spain, and its international presence currently extends across more than ten countries in Europe and Latin America. Its solutions are used by large companies across a variety of engineering-related sectors including construction and facilities management. With a network of over 1,000 contractors and 45,000 sub-contractors as of December 2023, Nalanda has one of the largest digital communities of suppliers globally.
GTCR, a leading private equity firm, acquired Once For All in 2023 in partnership with Chief Executive David Hornsby. PSG Equity, a growth equity firm that partners with software and technology-enabled services companies, acquired a majority stake in Nalanda in 2021. As part of the transaction, which is expected to close in the coming weeks, the PSG funds will retain a minority stake in the combined business.
David Hornsby, Chief Executive of Once For All, said:
“Nalanda is a well-established provider with a product suite that strategically complements our own, and we are enthusiastic about combining our strengths as we continue to grow Once For All across Europe. We are excited to welcome the Nalanda team to Once For All and we look forward to working together.”
Juan Gil Rabadan, Founder and CEO of Nalanda, said:
“Nalanda has gone through a transformative journey over the last three years under PSG’s ownership. Through the investment in people and product, both organically and via M&A, we’ve established Nalanda as an industry leader in supply chain risk and compliance management in Spain, with a growing international presence. We are now thrilled to join Once For All as we share a vision for supporting the built environment globally. We look forward to partnering with the Once For All team and continuing to invest in innovating our technology and capabilities to serve our customers.”
Mark Anderson, Managing Director and Head of Technology, Media & Telecommunications at GTCR, said:
“The combination of Once for All and Nalanda helps position the business for future growth through a pan-European offering. The combined company provides a leading technology platform and differentiated suite of products to help address the critical supply chain and compliance needs of its customers. We are pleased to partner with the PSG team and look forward to the continued success of the business.”
Dany Rammal, Managing Director at PSG Equity, said:
“PSG is proud to have been part of the journey to create a leading Spain-based software champion. Nalanda’s success to date is a testament to Juan Gil Rabadan’s vision and his entire team’s dedication to scaling the Company’s solution into a comprehensive supply chain risk management and compliance offering. We are excited to be continuing the journey alongside GTCR, David Hornsby and the entire Once For All management team in support of the combined company’s growth journey.”
About Once For All
Once For All is a European leader in supply chain risk management and sustainable sourcing solutions for the construction industry. We help our customers source and track sales opportunities, manage risk and compliance, and provide tools to increase efficiency in their supply chains. Once For All has over 150,000 customers that use its single codebase SaaS solution to search, find and assess future business relationships based on skills, trades and ESG credentials. As a result, Once For All manages one of the largest proprietary ESG data sets in the world. Once For All has over 400 employees, is the market leader in UK and France and has operations in Belgium and Germany. For more information, please visit www.onceforall.com.
About Nalanda Global
Nalanda is a Spanish supplier risk and compliance management platform founded in 2000. It leverages intelligent cloud software to help connect companies and suppliers using a digital platform that enables the smooth exchange and verification of health and safety, due diligence, supplier validation, invoices, ESG and other business information, as well as providing solutions designed to ensure compliance with worker access, and working time. Nalanda operates in Spain, as well as in several European and Latin American countries. For more information, please visit www.nalandaglobal.com.
About GTCR
Founded in 1980, GTCR is a leading private equity firm that pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $25 billion in over 270 companies, and the firm currently manages $40 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.
About PSG Equity
PSG is a growth equity firm that partners with software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 135 companies and facilitated 479 add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams. Founded in 2014, PSG operates out of offices in Boston, Kansas City, London, Madrid, Paris and Tel-Aviv. To learn more about PSG, visit www.psgequity.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403942729/en/
Contact information
Once For All
Arun Varma
arun.varma@onceforall.com
Nalanda
Goodwill Comunicación
Javier Herreros
jherreros@goodwill.es
GTCR
Andrew Johnson
Andrew.johnson@gtcr.com
PSG Equity
Prosek Partners
Matthieu Roussellier/Kate Pledger
Pro-psg@prosek.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom